REFERENCES
- Lee WS, Toh TH, Chai PF, Soo TL. Self-reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias. J Paediatr Child Health. 2011;47(8):535–540.
- Rashid M, Karimi M. Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran. Transfus Med. 2012;22(2):104–107.
- Viprakasit V, Lee-Lee C, Chong QT, et al. Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol. 2009;90(4):435–445.
- al-Refaie, FN, Veys, PA, Wilkes, S, Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one. Acta Haematol. 1993;89(2):86–90.
- Pennell DJ, Berdoukas V, Karagiorga M, Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738–3744.
- Daar S, Pathare AV. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload. Ann Hematol. 2006;85(5):315–319.
- Pepe A, Meloni A, Capra M, Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41–47.
- Cassinerio E, Roghi A, Pedrotti P, Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Ann Hematol. 2012;91(9):1443–1449.
- Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol. 2010;89(4):405–409.
- Cappellini MD, Porter J, El-Beshlawy A, Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95(4):557–566.
- Neufeld EJ. Update on iron chelators in thalassemia. Hematology Am Soc Hematol Educ Program. 2010;451–455.
- Meerpohl JJ, Antes G, Rücker G, Deferasirox for managing iron overload in people with thalassaemia Cochrane Database Syst Rev. 2012;2:CD007476.
- Wood JC, Tyszka JM, Ghugre N, Nelson MD, Coates TD. Myocardial iron loading in transfusion-dependent thalassaemia and sickle cell disease. Blood. 2004;103:1934–1936.
- Billaudel BJ, Delbancut AP, Sutter BC, Faure AG. Stimulatory effect of 1,25-dihydroxyvitamin D3 on calcium handling and insulin secretion by islets from vitamin D3-deficient rats. Steroids, 1999;58:335–341.
- Oudit GY, Sun H, Trivieri MG, L-type Ca(2+) channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. Nature, Medicine. 2003;9:1187–1194.
- Wood JC, Claster S, Carson S, , Vitamin D deficiency, cardiac iron and cardiac function in thalassaemia major, Br. J. Haematol. 2008;141(6):891–894.
- Al-Dhahry SH, Aghanashinikar PN, al-Hasani MK, Antibodies to hepatitis C virus in Omani patients with renal disease. Transplant Proc. 1992;24(5):1938–1939.
- Al-Dhahry SS, Aghanashinikar PN, Al-Marhuby HA, Hepatitis B, delta and human immunodeficiency virus infections among Omani patients with renal diseases: A seroprevalence study. Ann Saudi Med. 1994;14(4):312–315.